Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Sells $93,967.84 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 3,088 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $93,967.84. Following the sale, the chief financial officer now owns 129,211 shares of the company’s stock, valued at approximately $3,931,890.73. The trade was a 2.33 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Friday, January 17th, Timothy Eugene Sullivan sold 1,730 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total value of $51,830.80.
• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total value of $62,279.00.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS opened at $30.00 on Friday. The business has a fifty day simple moving average of $32.08 and a 200-day simple moving average of $33.15. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90. The company has a market cap of $3.73 billion, a P/E ratio of -14.78 and a beta of 0.94. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The business had revenue of $196.83 million during the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm’s quarterly revenue was up 78.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.17) EPS. Equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on APLS. The Goldman Sachs Group downgraded Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price target for the company. in a research note on Tuesday, December 17th. Wells Fargo & Company cut their target price on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Bank of America reduced their price target on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Oppenheimer cut their price objective on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, Mizuho lowered their target price on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a report on Thursday, October 24th. Eight analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Amalgamated Bank boosted its holdings in shares of Apellis Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after purchasing an additional 359 shares during the last quarter. KBC Group NV raised its position in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after buying an additional 679 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after acquiring an additional 781 shares during the last quarter. Wolverine Asset Management LLC purchased a new stake in Apellis Pharmaceuticals during the third quarter valued at about $27,000. Finally, True Wealth Design LLC acquired a new stake in Apellis Pharmaceuticals during the third quarter worth about $27,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).